Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes.
María Asunción Esteve-PastorJuan Miguel Ruíz-NodarEsteban Orenes-PiñeroJosé Miguel Rivera-CaravacaMiriam Quintana-GinerAndrea Véliz-MartínezAntonio Tello-MontoliuVicente PerniasEscrigMiriam Sandín RollánNuria Vicente-IbarraManuel Jesús MacíasVillanegoElena Candela SánchezLuna Carrillo AlemánTeresa LozanoMariano ValdésFrancisco MarínPublished in: Journal of cardiovascular pharmacology and therapeutics (2017)
In this real-life registry of patients with ACS, we observed there is still a high rate of use of clopidogrel, despite guidelines recommendations, and our analyses also showed a trend toward the use of ticagrelor. Patients who received new antiplatelet agents were patients with STEMI, younger than 75 years, and with less comorbidities. However, the use of ticagrelor and prasugrel remains low, highlighting a therapeutic inertia with considerable gap between evidence-based clinical guidelines and daily clinical practice.